Novel intracellular N-terminal truncated matrix metalloproteinase-2 isoform in skeletal muscle ischemia-reperfusion injury

Journal of Orthopaedic Research

Volumn 34, Issue 3, 2016, Pages 502-509

  Joshi, Sunil K ^a,b   Lee, Lawrence ^a   Lovett, David H ^a,b   Kang, Heejae ^a   Kim, Hubert T ^a,b   Delgado, Cynthia ^a,b   Liu, Xuhui ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

hindlimb ischemia reperfusion injury; hypoxia; matrix metalloproteinase 2; N terminal truncated matrix metalloproteinase 2; skeletal muscle

Indexed keywords

CXCL1 CHEMOKINE; GELATINASE A; INTERLEUKIN 6; ISOPROTEIN; N TERMINAL TRUNCATED MATRIX METALLOPROTEINASE 2; OAS 1A PROTEIN; PROTEIN; PYRROLIDINE DITHIOCARBAMATE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ISOENZYME; MMP2 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INNATE IMMUNITY; MOUSE; MUSCLE INJURY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REPERFUSION INJURY; SKELETAL MUSCLE; SKELETAL MUSCLE ISCHEMIA REPERFUSION INJURY; UPREGULATION; ANIMAL; CELL LINE; ENZYMOLOGY; HYPOXIA; METABOLISM; VASCULARIZATION;

ANIMALS; CELL LINE; HYPOXIA; ISOENZYMES; MATRIX METALLOPROTEINASE 2; MICE; MUSCLE, SKELETAL; REPERFUSION INJURY; TOLL-LIKE RECEPTOR 4; UP-REGULATION;

EID: 84959229136     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22992     Document Type: Article

References (49)

1. Zweier JL, Talukder MA,. 2006. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 70: 181-190.
2. Gillani S, Cao J, Suzuki T, et al., 2012. The effect of ischemia reperfusion injury on skeletal muscle. Injury 43: 670-675.
3. Lyden SP, Shortell CK, Illig KA,. 2001. Reperfusion and compartment syndromes: strategies for prevention and treatment. Semin Vasc Surg 14: 107-113.
4. Klenerman L,. 1980. Tourniquet time-how long? Hand 12: 231-234.
5. Whalen DA, Jr., Hamilton DG, Ganote CE, et al., 1974. Effect of a transient period of ischemia on myocardial cells. I. Effects on cell volume regulation. Am J Pathol 74: 381-397.
6. Piper HM, Garcia-Dorado D,. 1999. Prime causes of rapid cardiomyocyte death during reperfusion. Ann Thorac Surg 68: 1913-1919.
7. Gross GJ, Kersten JR, Warltier DC,. 1999. Mechanisms of postischemic contractile dysfunction. Ann Thorac Surg 68: 1898-1904.
8. Hori K, Tsujii M, Iino T, et al., 2013. Protective effect of edaravone for tourniquet-induced ischemia-reperfusion injury on skeletal muscle in murine hindlimb. BMC Musculoskelet Disord 14: 113.
9. Dejonckheere E, Vandenbroucke RE, Libert C,. 2011. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov Today 16: 762-778.
10. Nagase H, Woessner JF, Jr., 1999. Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
11. Planas AM, Sole S, Justicia C,. 2001. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 8: 834-846.
12. Zhou HZ, Ma X, Gray MO, et al., 2007. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun 358: 189-195.
13. Dahi S, Karliner JS, Sarkar R, et al., 2011. Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. Int J Exp Pathol 92: 50-56.
14. Kunugi S, Shimizu A, Kuwahara N, et al., 2011. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab Invest 91: 170-180.
15. Novak KB, Le HD, Christison-Lagay ER, et al., 2010. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res 67: 257-262.
16. Roach DM, Fitridge RA, Laws PE, et al., 2002. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg 23: 260-269.
17. Lovett DH, Mahimkar R, Raffai RL, et al., 2012. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS ONE 7: e34177.
18. Lovett DH, Mahimkar R, Raffai RL, et al., 2013. N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS ONE 8: e68154.
19. Lovett DH, Chu C, Wang G, et al., 2014. A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Front Physiol 5: 363.
20. Crawford RS, Hashmi FF, Jones JE, et al., 2007. A novel model of acute murine hindlimb ischemia. Am J Physiol Heart Circ Physiol 292: H830-H837.
21. Albadawi H, Oklu R, Cormier NR, et al., 2014. Hind limb ischemia-reperfusion injury in diet-induced obese mice. J Surg Res 190: 683-691.
22. Joshi SK, Liu X, Samagh SP, et al., 2013. MTOR regulates fatty infiltration through SREBP-1 and PPARgamma after a combined massive rotator cuff tear and suprascapular nerve injury in rats. J Orthop Res 31: 724-730.
23. Schmittgen TD, Livak KJ,. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
24. Shimkunas R, Makwana O, Spaulding K, et al., 2014. Myofilament dysfunction contributes to impaired myocardial contraction in the infarct border zone. Am J Physiol Heart Circ Physiol 307: H1150-H1158.
25. Yucel M, Kucuk A, Bayraktar AC, et al., 2013. Protective effects of the nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate in bladder ischemia-reperfusion injury in rats. Mol Biol Rep 40: 5733-5740.
26. Rosenberg GA, Navratil M, Barone F, et al., 1996. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 16: 360-366.
27. Hadler-Olsen E, Solli AI, Hafstad A, et al., 2015. Intracellular MMP-2 activity in skeletal muscle is associated with type II fibers. J Cell Physiol 230: 160-169.
28. Ali MA, Chow AK, Kandasamy AD, et al., 2012. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol 227: 3397-3404.
29. Wang W, Schulze CJ, Suarez-Pinzon WL, et al., 2002. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549.
30. Ferreira R, Vitorino R, Alves RM, et al., 2010. Subsarcolemmal and intermyofibrillar mitochondria proteome differences disclose functional specializations in skeletal muscle. Proteomics 10: 3142-3154.
31. Drew B, Leeuwenburgh C,. 2004. Ageing and subcellular distribution of mitochondria: role of mitochondrial DNA deletions and energy production. Acta Physiol Scand 182: 333-341.
32. Fan H, Sun B, Gu Q, et al., 2002. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 282: H1778-H1786.
33. Maulik N, Sasaki H, Addya S, et al., 2000. Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett 485: 7-12.
34. Gupta S, Young D, Maitra RK, et al., 2008. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 375: 637-649.
35. Gordon JW, Shaw JA, Kirshenbaum LA,. 2011. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 108: 1122-1132.
36. Ilbey YO, Ozbek E, Simsek A, et al., 2009. Chemoprotective effect of a nuclear factor-kappaB inhibitor, pyrrolidine dithiocarbamate, against cisplatin-induced testicular damage in rats. J Androl 30: 505-514.
37. Kumar S, Seqqat R, Chigurupati S, et al., 2011. Inhibition of nuclear factor kappaB regresses cardiac hypertrophy by modulating the expression of extracellular matrix and adhesion molecules. Free Radic Biol Med 50: 206-215.
38. Cau SB, Guimaraes DA, Rizzi E, et al., 2011. Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension. Br J Pharmacol 164: 372-381.
39. Alfonso-Jaume MA, Bergman MR, Mahimkar R, et al., 2006. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 291: H1838-H1846.
40. Lee JG, Dahi S, Mahimkar R, et al., 2005. Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci USA 102: 16345-16350.
41. Bergman MR, Cheng S, Honbo N, et al., 2003. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 369: 485-496.
42. Liu X, Manzano G, Lovett DH, et al., 2010. Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochem Biophys Res Commun 396: 219-223.
43. Mann DL,. 2011. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 108: 1133-1145.
44. Arslan F, de Kleijn DP, Pasterkamp G,. 2011. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 8: 292-300.
45. Arumugam TV, Okun E, Tang SC, et al., 2009. Toll-like receptors in ischemia-reperfusion injury. Shock 32: 4-16.
46. Warren GL, Hulderman T, Liston A, et al., 2011. Toll-like and adenosine receptor expression in injured skeletal muscle. Muscle Nerve 44: 85-92.
47. Frost RA, Nystrom GJ, Lang CH,. 2006. Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am J Physiol Regul Integr Comp Physiol 290: R773-R784.
48. Oyama J, Blais C, Jr., Liu X, et al., 2004. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109: 784-789.
49. Chong AJ, Shimamoto A, Hampton CR, et al., 2004. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 128: 170-179.